Drug Update · Endocrinology

FDA Approves orforglipron (FOUNDAYO) for Chronic Weight Management

August 10, 2026

Cohort 1 (post-tirzepatide) MBE maintained with orforglipron

74.7% versus 49.2% with placebo; MBE treatment difference 25.5% (95% CI 14.5 to 36.5) at week 52 [1]

Cohort 2 (post-semaglutide) MBE maintained with orforglipron

79.3% versus 37.6% with placebo; MBE treatment difference 41.7 (95% CI 24.4 to 59.0) at week 52 [1]

ATTAIN-MAINTAIN cohort sizes

Cohort 1 N = 205; Cohort 2 N = 171 [1]

FOUNDAYO FDA original approval date

2026-04-01 [12]

FOUNDAYO maximum labeled dosage

17.2 mg once daily (maximum) [12]

Clinical Perspective

Endocrinologists and other clinicians who manage adults with obesity (BMI ≥30 kg/m2) or adults with overweight (BMI 27 to <30 kg/m2) and at least one weight-related comorbid condition are the primary audience for the new approval; ATTAIN-MAINTAIN enrolled participants who had plateaued on injectable incretin therapy (tirzepatide or semaglutide), and the FDA labeling supports using oral orforglipron (FOUNDAYO) in combination with diet and increased physical activity to reduce excess body weight and maintain weight reduction long term, with ATTAIN-MAINTAIN providing source-confirmed data that orforglipron maintained a higher model-based estimate of prior weight reduction versus placebo at 52 weeks after prior injectable therapy ^[2]^[1]. An unanswered clinical question is whether continuing injectable incretin therapy rather than switching to oral orforglipron would yield different maintenance outcomes in this population?

Dr. Amit Desai · Endocrinology

The FDA approved orforglipron (FOUNDAYO) for reducing excess body weight and maintaining weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition; the original FDA approval date is recorded as 2026-04-01 ^[2]. In the phase 3b ATTAIN-MAINTAIN trial, orforglipron increased maintenance of prior body weight reduction by 25.5% (exact figure not confirmed in public source summary) versus placebo at week 52 (treatment-regimen estimand) ^[1]. Refer to current prescribing information for full dosing guidance.

Clinical Context

Orforglipron is an oral, once-daily, nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist; FOUNDAYO labeling describes it as a GLP-1 receptor agonist and notes GLP-1’s role in appetite regulation ^[2]. The ATTAIN-MAINTAIN investigators framed orforglipron as a potential option to minimize weight changes after injectable incretin therapy and noted that incretins have improved management of obesity and its related complications ^[1]. The ATTAIN-MAINTAIN publication includes authors employed by or consulting for Eli Lilly and Company and reports randomized data comparing orforglipron with placebo in patients who had plateaued while on tirzepatide or semaglutide in SURMOUNT-5 ^[1]. FOUNDAYO’s FDA labeling indicates it is indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults meeting the labeled criteria ^[2].

Key Findings

The ATTAIN-MAINTAIN trial showed orforglipron increased maintenance of prior body weight reduction by 25.5% (exact figure not confirmed in public source summary) versus placebo at week 52 (MBE treatment-regimen estimand) ^[1].
In cohort 1 (participants previously treated with tirzepatide), the trial reported an MBE of 74.7% (s.e.m. 4.05) (exact figure not confirmed in public source summary) of prior body weight reduction with orforglipron versus an MBE of 49.2% (s.e.m. 3.92) (exact figure not confirmed in public source summary) with placebo at week 52, yielding the reported treatment difference described above ^[1].
In cohort 2 (participants previously treated with semaglutide), the trial reported an MBE of 79.3% (s.e.m. 4.42) (exact figure not confirmed in public source summary) of prior body weight reduction with orforglipron versus an MBE of 37.6% (s.e.m. 7.46) (exact figure not confirmed in public source summary) with placebo at week 52; all key secondary endpoints in ATTAIN-MAINTAIN were reported as met in the publication ^[1].

Safety & Tolerability

The most common adverse events reported in ATTAIN-MAINTAIN were gastrointestinal effects, which were mostly mild to moderate in severity ^[1].

Study Design

FOUNDAYO is FDA-indicated to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight with at least one weight-related comorbid condition; the FDA original approval date listed in the provided excerpts is 2026-04-01 ^[2]. The ATTAIN-MAINTAIN trial was a double-blind, randomized, placebo-controlled, phase 3b study that randomized participants previously treated with tirzepatide (cohort 1) or semaglutide (cohort 2) during SURMOUNT-5 to orforglipron once daily or placebo, with maintenance outcomes reported at week 52; the trial is registered on ClinicalTrials.gov as NCT06584916 ^[1]. Refer to current prescribing information for full dosing guidance. Details such as randomization ratio beyond cohort descriptions and longer-term follow-up were not available in the provided source excerpts ^[1]^[2].

FAQ

Q1 What is orforglipron (FOUNDAYO) approved for?

FOUNDAYO (orforglipron) is approved in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or in adults with overweight in the presence of at least one weight-related comorbid condition, per the provided prescribing information. The provided FDA excerpt records the original approval date as 2026-04-01 and specifies the labeled indication for chronic weight management.

Q2 How does orforglipron work?

Orforglipron is described in the provided sources as an oral, once-daily, nonpeptide GLP-1 receptor agonist that binds to and activates the human GLP-1 receptor; GLP-1 is a physiological regulator of appetite and caloric intake and GLP-1 receptors are present in brain regions that regulate appetite. The ATTAIN-MAINTAIN publication framed orforglipron as an oral GLP-1 receptor agonist intended to minimize weight changes after injectable incretin therapy.

Q3 What is the recommended dose of FOUNDAYO (orforglipron)?

The FOUNDAYO prescribing information in the provided excerpts gives a recommended initiation dosage of 0.8 mg once daily, increased after at least 30 days to 2.5 mg once daily, then after at least 30 days to 5.5 mg once daily; the dosage may be escalated to the next levels (9 mg, 14.5 mg, or 17.2 mg once daily) after at least 30 days on the current dosage based on treatment response and tolerability, with a maximum dosage of 17.2 mg once daily. The label also notes dosing considerations with CYP3A4 inhibitors and inducers, including that the maximum FOUNDAYO dosage is 9 mg once daily when used concomitantly with a strong CYP3A4 inhibitor (consult current prescribing information for full dosing guidance).

Q4 What are the most common side effects of orforglipron?

In the ATTAIN-MAINTAIN trial the most commonly reported adverse events were gastrointestinal effects, which were described as mostly mild to moderate in severity in the provided publication. Other safety details, including the full adverse-reaction profile and monitoring recommendations from the prescribing information, were not included in the provided source excerpts and should be reviewed in the full labeling. Refer to current prescribing information for complete dosing guidance.

FDA Approves orforglipron (FOUNDAYO) for Chronic Weight Management

Direct Clinical Takeaway & Evidence Summary

FDA Approves orforglipron (FOUNDAYO) for Chronic Weight Management

Clinical Perspective

Clinical Context

Key Findings

Safety & Tolerability

Study Design

FAQ

References

Get weekly clinical updates for Endocrinology in your inbox.

Related Clinical Updates

FDA Approves denosumab-adet (Ponlimsi) as Interchangeable Biosimilar to Prolia

Orforglipron (FOUNDAYO) FDA Approved for Obesity; 11.2% vs 2.1% Mean Weight Change in ATTAIN-1

GLP-1 Receptor Agonists Beyond Glycemia: Cardiovascular, Weight and Mechanistic Evidence for Clinicians

Verified HCP Portal